A total of 22 patients with acute myeloid leukemia (AML) in first complete remission receiving autologous blood stem cell transplantation (ABSCT) were investigated in order to determine factors affecting outcome. All but two patients had a normal karyotype and received the same high-dose chemotherapy followed by G-CSF-mobilized peripheral blood stem cells after the second (n ¼ 5) or third (n ¼ 17) course of induction and post-remission chemotherapy, respectively. With a median follow-up of 30 months, the median disease-free survival is 24.1 months. Univariate analysis showed that three chemotherapy cycles before ABSCT were associated with a significant better disease-free survival (P ¼ 0.0018) and overall survival (P ¼ 0.0033), whereas the presence of an FLT3-mutation (n ¼ 6) showed no impact. The number of megakaryocytic progenitors (CFU-MK) infused tended to correlate with primary platelet engraftment (P ¼ 0.07) and were predictive for neutrophil (P ¼ 0.011) and platelet counts (P ¼ 0.009) 180 days after transplantation. Patients receiving a higher amount of CFU-MK had a better event-free survival (P ¼ 0.02). Our data suggest that the content of CFU-MK within the graft predicts the quality of hematological recovery and long-term disease control. Additionally, a minimum of three chemotherapy cycles before ABSCT seems to be associated with an improved outcome.
Summary:
A total of 22 patients with acute myeloid leukemia (AML) in first complete remission receiving autologous blood stem cell transplantation (ABSCT) were investigated in order to determine factors affecting outcome. All but two patients had a normal karyotype and received the same high-dose chemotherapy followed by G-CSF-mobilized peripheral blood stem cells after the second (n ¼ 5) or third (n ¼ 17) course of induction and post-remission chemotherapy, respectively. With a median follow-up of 30 months, the median disease-free survival is 24.1 months. Univariate analysis showed that three chemotherapy cycles before ABSCT were associated with a significant better disease-free survival (P ¼ 0.0018) and overall survival (P ¼ 0.0033), whereas the presence of an FLT3-mutation (n ¼ 6) showed no impact. The number of megakaryocytic progenitors (CFU-MK) infused tended to correlate with primary platelet engraftment (P ¼ 0.07) and were predictive for neutrophil (P ¼ 0.011) and platelet counts (P ¼ 0.009) 180 days after transplantation. Patients receiving a higher amount of CFU-MK had a better event-free survival (P ¼ 0.02). Our data suggest that the content of CFU-MK within the graft predicts the quality of hematological recovery and long-term disease control. Additionally, a minimum of three chemotherapy cycles before ABSCT seems to be associated with an improved outcome. A recent meta-analysis has shown that there is only limited scientific evidence for the use of autologous bone marrow transplantation as consolidation treatment in patients with acute myeloid leukemia in first complete remission. Nevertheless, within the past years autologous blood stem cell transplantation (ABSCT) has become a new and widely used treatment strategy in patients with acute myeloid leukemia (AML). Although it has been shown to be associated with a moderate toxicity and lower treatmentrelated mortality compared to bone marrow, its value in subgroups of AML patients is still a question of debate. In fact, patients with favourable or intermediate cytogenetics seem to benefit from this procedure, 2 although randomized trials are missing. Recently, activating FLT3 receptor mutations have been shown to distinguish a poor-risk patient population out of those with normal karyotype. Preliminary data suggest that FLT-mutation status is associated with a higher risk for relapse even after autologous and allogeneic transplantation.
3 It is not known whether the increased relapse risk can also be observed after ABSCT. There are also conflicting data whether the number of chemotherapy courses affects outcome after ABSCT. 4, 5 Additionally, several studies have defined distinct parameters influencing the hematopoietic reconstitution and long-term disease-free survival in these patients. [6] [7] [8] [9] This includes the effects of progenitor cell count within the graft on engraftment speed. There is only one study suggesting that the amount megakaryocytic progenitors (CFU-MK) infused affects disease-free survival after ABSCT, whereas other lineage-associated colony assays had no impact. 10 This is important since several patients with AML do not show complete hematological recovery after autologous transplantation 11 and CFU-MK are decreased in diseases with marrow failure like MDS. Therefore, it might be of interest to correlate megakaryocytic colony formation with hematopoietic reconstitution after ABSCT.
Therefore, we prospectively investigated parameters affecting outcome in 22 patients with AML receiving an ABSCT after two or three courses of induction chemotherapy.
Patients and methods
Patient characteristics are shown in Table 1 . All patients were treated within the AML 96 protocol of the DSIL study group. 12 The study was approved by the local institutional review board. Patients below the age of 65 years with de novo AML, as defined by the FrenchAmerican-British (FAB) classification, were eligible for the study. All included patients gave written informed consent. Patients were considered for ABSCT if they had intermediate-risk cytogenetics (normal karyotype, inv16) or high-risk cytogenetic features in case of the absence of an HLA-matched related or unrelated donor. The FLT3-mutation status was performed as described, 13 and had no impact on risk stratification in this trial. , n ¼ 9). During chemotherapyinduced cytopenia, G-CSF-induced peripheral blood stem cell (PBSC) mobilization was performed after the second IC in all 22 patients and in patients within group B a second time after CT. The latter group received only the graft obtained after the consolidation course.
Chemotherapy

Leukapheresis procedure
During chemotherapy-induced cytopenia, patients received recombinant human G-CSF at a dosage of 10 mg/kg/day. In case of an increase of the percentage of CD34 þ cells over a certain threshold in the peripheral blood, leukapheresis was started. CD34 þ cells were quantified by flow cytometric analysis.
14 Venous access was obtained through venipuncture of both arms. A large volume apheresis comprising four times the calculated patient's blood volume was performed using a continuous-flow cell separator (Cobe Spectra, Lakewood, USA). After collection, the cells were placed in 10% (v/v) dimethylsulfoxide (DMSO) and stored in liquid nitrogen at À1961C until use.
Analysis of colony-forming unit-granulocyte-macrophage (CFU-GM) and CFU-MK
For quantification of progenitor content, 1 Â 10 5 mononuclear cells diluted in PBS Dulbecco's w/o Ca and Mg (Bio Whittaker, Walkersville, Maryland, USA) were plated in a complete methylcellulose medium containing IMDM with 30% fetal bovine serum, 3 U/ml erythropoietin, 50 ng/ml SCF, 20 ng/ml GM-CSF, 20 ng/ml IL-3, 20 ng/ml IL-6 and 20 ng/ml G-CSF (Methocult GF H4435, Stem Cell Technologies, Vancouver, Canada). Cultures were incubated at 371C and 5% CO 2 . The cultures were assessed at day 14 for the presence of burst-forming uniterythroid (BFU-E), CFU-GM and mixed colony-forming unit (CFU-GEMM).
The content of CFU-MK was determined using the Stem a.II-Mega Kit (Tebu-Bio GmbH, Offenbach, Germany) according to the manufacturer's instructions. In brief, 1 Â 10 5 MNC were suspended in 1 ml of a complete methylcellulose medium containing IMDM with 30% fetal bovine serum, 20 ng/ml IL-3, 20 ng/ml IL-6, 50 ng/ml IL-11, 20 ng/ml SCF, 20 ng/ml bFGF and 30 ng/ml rhTPO. Colonies were scored after 12 days of culture at the conditions mentioned above. The counted numbers were calculated and expressed as the number of colonies per patient body weight at the time of ABSCT.
Conditioning regimen
All patients were conditioned with busulfan 4 mg/kg p.o. in divided doses daily for 4 days (total dose 16 mg/kg) on days À7 to À4, etoposide once 30 mg/kg i.v. on day À3 and cyclophosphamide 60 mg/kg once daily i.v. on days À3 and À2 (total dose 120 mg/kg). On day 0, the cryopreserved stem cells were thawed and reinfused. Neutrophil engraftment was defined as the first of three consecutive days with an absolute neutrophil count (ANC) of greater than 0.5 Â 10 9 /l independently of the administration of G-CSF. Platelet recovery was defined as the first of three consecutive days of a sustained absolute platelet count of greater than 20 Â 10 9 /l without any transfusion support.
Statistical analysis
Quantitative parameters are given as median with maximum and minimum. Comparisons of the median between both groups were performed with the Wilcoxon test. An univariate analysis was used in order to estimate the effect of covariates like number of transplanted CD34 þ cells, total cell number collected, patient age, therapy before transplantation, cytogenetics, CFUs, FLT3 receptor status and timing of stem cell harvest (LPH) on overall survival, disease-free survival and probability of relapse.
Kaplan-Meier estimates of survival and log-rank tests for comparisons are provided whenever appropriate. Correlation coefficients between transplanted cells, CFU-GM and MK-colonies and platelet and neutrophil counts 30, 60, 100, 180 and 360 days after ABSCT were calculated using the Pearson's statistics. The analyses were performed using the SPSS software programme (Chicago, IL, USA).
Results
Transplantation and engraftment
A median of 2.33 Â 10 6 /kg CD34 þ cells (range 1.2-4.85) were infused on day 0 (Table 2 ). There was a significant (P ¼ 0.048) difference between the number of CD34 þ cells in the graft between group A (3.2 Â 10 6 /kg (range 1.9-4.8)) and B (2.2 Â /l was 11 days (range 9-19) and 13.5 days (range 1-159), respectively. There was no statistically significant difference between both groups.
Factors influencing hematopoietic reconstitution
The median ANC on days 30, 180 and 360 after transplant was 1.44 Â /l (range 23-205) was documented, respectively. In fact, there were three patients failing to achieve normal blood counts (ANC 41.5 Â 10 9 /l, platelets 4100 Â 10 9 /l) 180 and 360 days after ABSCT. The factors significantly affecting neutrophil and platelet recovery in the univariate analysis were the CFU-MK, CFU-GM dose and the number of transplanted CD34 þ cells infused (Table 3) . Age and total cell number infused had no impact on the kinetics of engraftment. All values are P-values and the correlation coefficient; PLT ¼ platelets; ANC ¼ absolute neutrophil count; the number given is the day after transplantation. All values are provided as median (range), group A (transplantation after second cycle of induction chemotherapy), group B (transplantation after third cycle of induction/post-remission chemotherapy).
Factors influencing outcome
With a median follow-up of 30 months, the median overall survival had not been reached and the disease-free survival was 24.1 months (Figure 1a and b) . Only one patient died while being in remission due acute cardiac failure 11 days after ABSCT. Nine patients relapsed a median of 8.6 months after ABSCT (Figure 1c ), three of them had received only two cycles of induction chemotherapy, none had high-risk cytogenetics and three out of nine were FLT3 positive. The number of therapies before ABSCT (2 vs 3) affected overall and disease-free survival (Figure 2a and b) as well as the probability of relapse (P ¼ 0.0033, 0.0018 and 0.0103). In line with this, observation time of stem cell harvesting (stem cells obtained after the second or the third IC) had an impact on overall and disease-free survival (P ¼ 0.0082 and 0.0209). Besides, CFU-MK had also a significant influence on the duration of disease-free survival and the probability of relapse (P ¼ 0.0274 and 0.0465; Figure 3 ). Interestingly, FLT3-mutation status had no impact on all parameters (data not shown), with a total of 1 and 5 FLT3-positive patients treated in groups A and B, respectively.
Discussion
With the availability of PBSC as stem cell source, there is growing interest in applying ABSCT as treatment strategy in patients with newly diagnosed AML. Our data show that the procedure is associated with a low treatment-related mortality and can result in disease control in patients with intermediate-risk AML defined by cytogenetics. It is also promising that both patients with high-risk cytogenetics did not relapse, although data from other studies suggest that ABSCT is no option for this patient population. Nevertheless, we confirm that ABSCT after two cycles of IC is insufficient to achieve long-term disease control. 15 This suggests an insufficient in vivo purging as a result of only two courses of induction chemotherapy. There is a long tradition of graft-purging using autologous bone marrow grafts in patients with AML. Although prospective trials could never be performed, retrospective analyses suggested purging of clonogenic leukemia progenitors from the graft could have a positive impact on disease-free survival. 16 This experience also argues for the importance to obtain an autologous graft with as less as possible leukemic contamination. On the other hand, the favourable outcome of the subgroup of patients mobilizing enough CD34 þ cells after the third chemotherapy cycle could be a selection bias.
We observed a comparable outcome of FLT3-positive patients. Since these mutations have been shown to negatively affect outcome, ABSCT might be the treatment of choice for these patients. 17 In contrast to other reports, we could not show that the CD34 þ concentration had an influence on the hematopoietic recovery. This might be due to the low number of patients studied in this analysis. On the other hand, the intensity of induction chemotherapy containing intermediate-dose cytosine-arabinoside in our protocol might have led to successful mobilization only in a limited percentage of patients.
We confirm the data showing the influence of CFU-GM on hematopoietic recovery. Nevertheless, little data are available on the role of CFU-MK. We show here that there is indeed a correlation, especially with long-term platelet and neutrophil reconstitution, which is not infrequently incomplete in patients after transplant. 18 It is of note that we were able to confirm the data by Reichle et al 19 on the impact of CFU-MK on long-term disease control. Therefore, this assay might be a simple tool in order to estimate the prognosis of an individual patient. Of course, the colonies quantified with the commercial assay used in this series are not merely restricted to CFU-MK, but perhaps provide a more accurate assessment of the clonogenicity of the autologous graft compared to the CFU-GM assay used. Given the relatively short follow-up in our analyses, the prognostic role of graft clonogenicity and cycles of pretreatment on disease-free survival with respect to other risk factors has to be regarded with caution.
In patients receiving three cycles prior to ABSCT, the disease-free survival reached 49%. Although the patient number is limited in our study, these data at least provide some rationale to believe that ABSCT may be a reasonable strategy in this patient population. 20 Nevertheless, randomized studies comparing chemotherapy with ABSCT will have to confirm our observation since the majority of published trials used bone marrow as stem cell source. 
